MBX — MBX Biosciences Share Price
0.000.00%
Last trade - 00:00- $306.50m
- $44.35m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.19 | ||
| Price to Tang. Book | 1.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.48% | ||
| Return on Equity | -36.71% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 9th, 2019
- Public Since
- September 13th, 2024
- No. of Shareholders
- 71
- No. of Employees
- 43
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 33,424,371
- Address
- 11711 N. Meridian Street, Suite 300, CARMEL, 46032
- Web
- https://mbxbio.com/
- Phone
- +1 3179893100
- Auditors
- Ernst & Young LLP
Upcoming Events for MBX
MBX Biosciences Inc at RBC Capital Markets Global Healthcare Conference
MBX Biosciences Inc Annual Shareholders Meeting
Similar to MBX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the MBX Biosciences share price?
As of Today at 21:57 UTC, shares in MBX Biosciences are trading at $9.17. This share price information is delayed by 15 minutes.
How has the MBX Biosciences share price performed this year?
Shares in MBX Biosciences last closed at $9.17 and the price had moved by over the past 365 days. In terms of relative price strength the MBX Biosciences share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for MBX Biosciences?
The overall consensus recommendation for MBX Biosciences is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the MBX Biosciences dividend yield?
MBX Biosciences does not currently pay a dividend.
Does MBX Biosciences pay a dividend?
MBX Biosciences does not currently pay a dividend.
When does MBX Biosciences next pay dividends?
MBX Biosciences does not currently pay a dividend.
How do I buy MBX Biosciences shares?
To buy shares in MBX Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MBX Biosciences?
As of the previous close price of $9.17, shares in MBX Biosciences had a market capitalisation of $306.50m.
Where are MBX Biosciences shares listed?
Here are the trading details for MBX Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MBX
What kind of share is MBX Biosciences?
Based on an overall assessment of its quality, value and momentum MBX Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MBX Biosciences share price forecast for 2025?
The analyst consensus target price for shares in MBX Biosciences is $37.40. That is 307.85% above the last closing price of $9.17.
Analysts covering MBX Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$2.82 for the next financial year.
Find out moreWhat is the trend in the MBX Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MBX Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -54.5%.
As of the last closing price of $9.17, shares in MBX Biosciences were trading -41.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MBX Biosciences PE Ratio?
The MBX Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MBX Biosciences?
We do not have data on MBX Biosciences' directors